Moderna said it filed for FDA Emergency Use Authorization of its Covid-19 booster for all adults ages 18 and older.
Pfizer, BioNTech Up on Report FDA May Give Booster Nod Thursday
- Moderna Inc. rose 5.09% to USD246 as of 1:23 p.m. New York time
- The average 12-month price target of $286 is 16% above the current price
- 9 buys, 5 sells, 5 holds
To view the source of this information, click
To contact the reporter on this story:
To contact the editor responsible for this story: